Join Essenvia at RAPS Convergence 2026 — Booth #918
· Charlotte, 15–17 September
Read more →
Reports & Guides
In-depth reports, practical guides and recorded sessions for medical device regulatory teams.
Webinar
Regulatory AI Innovation for MedTech RA Teams
Regulatory affairs teams are being asked to move faster, reduce manual work, and accelerate market access while managing increasing regulatory complexity. This RAPS Euro Convergence presentation shows how MedTech RA teams can use regulatory AI to achieve measurable value quickly, build trust, and scale responsibly.
Report
Regulatory Affairs, RIMS and AI
The Top 5% Playbook: Prepare your Regulatory Affairs team for a successful AI RIMS rollout
Report
An AI-Powered RIMS Solution that Works: Lessons from Terumo's Rollout
Discover the proven 7-step playbook that helped Terumo Medical Corporation launch their AI-powered RIMS in under 90 days—and learn why 95% of AI implementations fail while theirs succeeded. Featuring insights from RAPS Convergence 2025
Report
The New RA Playbook to Balance FDA Staff Reduction, AI, and Tariffs
A downloadable playbook on balancing FDA staff reductions, AI adoption and tariff pressure in regulatory planning.
Webinar
Digital Transformation in MedTech Reg Affairs: A "Must" or a "Nice to Have"?
MedTech transformation and how it connects to digital transformation is explored in this presentation from the 2024 MedTech Summit in Brussels. Viewers will gain insight into top digital priorities that medical device company executives and leaders are actively pursuing, the myriad challenges regulatory affairs professionals face in this space, and much more.
Webinar
2024 State of US MedTech Regulation
This timely webinar dissects the recent US MedTech regulatory landscape for a number of topics, including medical device innovation and digital transformation, AI and machine learning, US FDA product submissions, and much more. Based on a sweeping 30-page Essenvia expert report, viewers will learn strategic insights, guidance, and best practices to navigate shifting regulatory expectations in 2024 and beyond.